Remove Electronics Remove Patients Remove Prescription Remove Safety
article thumbnail

‘The Stakes Couldn’t Be Higher’: How DEA’s Proposal Will Affect Telehealth Controlled Substance Prescribing

MedCity News

The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. The European Medicines Agency (EMA) underscores the role of digital platforms in disseminating product information electronically.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DTC forecasts are not really that reliable

World of DTC Marketing

billion, making it the fastest-growing sector after computing products and consumer electronics (which will grow 18.0% What’s missing, however, is the need to get patients back into their doctor’s offices for treatments and bothersome health issues. to reach $9.53 this year). How reliable is this estimate?

Doctors 227
article thumbnail

What are the Benefits of Having an EHR?

Referral MD

After implementing the 2009 Health Information Technology for Economic and Clinical Health (HITECH) Act, US clinics were provided sufficient funds to adapt to newer electronic practices in data recording. As a result, 76% of healthcare practices utilized the benefits of Electronic Health Record (EHR) software. What is an EHR?

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. But it is not a simple answer. Furthermore, it is estimated to reach $6.5 Vincent Keunen.

article thumbnail

Curavit’s crystal ball – how will 2023 drive meaningful changes in clinical research

pharmaphorum

The life sciences industry is flexing towards innovation in new areas, faster than ever before, and increasing patient care in astonishing ways. We can now measure patient activity, steps, and movement continuously and in real time, which serves as a new potential indicator of treatment effectiveness.

FDA 86
article thumbnail

Two Key Questions About Adherence/Compliance in 2022

PM360

The industry has been limited in its ability to implement creative solutions to engage and motivate patients because the FDA has strict guidelines for what pharma companies can communicate with patients. Today, we still can’t easily discern whether a patient took their pill or not and the reason why. Michael Oleksiw.

Medical 105